scholarly journals Lowering Blood Pressure With β-Blockers in Combination With Other Renin-Angiotensin System Blockers in Patients With Hypertension and Type 2 Diabetes: Results From the GEMINI Trial

2007 ◽  
Vol 9 (11) ◽  
pp. 842-849 ◽  
Author(s):  
Jackson T. Wright ◽  
George L. Bakris ◽  
David S. H. Bell ◽  
Vivian Fonseca ◽  
Richard E. Katholi ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Renin Angiotensin System ◽  
Angiotensin System ◽  
Renin Angiotensin ◽  
Β Blockers ◽  
Renin Angiotensin System Blockers

scholarly journals Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes

2017 ◽  
Vol 65 (7) ◽  
pp. 1057-1061 ◽  
Author(s):  
Takuo Yoshimoto ◽  
Takayuki Furuki ◽  
Hiroyuki Kobori ◽  
Masaaki Miyakawa ◽  
Hitomi Imachi ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Renin Angiotensin System ◽  
Sglt2 Inhibitors ◽  
Creatinine Ratio ◽  
Angiotensin System ◽  
Renin Angiotensin ◽  
Urinary Angiotensinogen ◽  
Sodium Glucose Cotransporter

We conducted a descriptive case study to examine the effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on urinary angiotensinogen excretion, which represents the function of the intrarenal renin–angiotensin system, in patients with type 2 diabetes. An SGLT2 inhibitor (canagliflozin 100 mg/day, ipragliflozin 25 mg/day, dapagliflozin 5 mg/day, luseogliflozin 2.5 mg/day or tofogliflozin 20 mg/day) was administered for 1 month (n=9). ELISA kits were used to measure both urinary intact and total angiotensinogen levels. Treatment with SGLT2 inhibitors significantly decreased hemoglobin A1c, body weight, systolic blood pressure and diastolic blood pressure (8.5±1.3 to 7.5%±1.0%, 82.5±20.2 to 80.6±20.9 kg, 143±8 to 128±14 mm Hg, 78±10 to 67±9 mm Hg, p<0.05, respectively), while urinary albumin/creatinine ratio was not significantly changed (58.6±58.9 to 29.2±60.7 mg/g, p=0.16). Both total urinary angiotensinogen/creatinine ratio and intact urinary angiotensinogen/creatinine ratio tended to decrease after administration of SGLT2 inhibitors. However, these changes were not significant (p=0.19 and p=0.08, respectively). These data suggest that treatment with SGLT2 inhibitors does not activate the intrarenal renin–angiotensin system in patients with type 2 diabetes.

scholarly journals Effects of the Renin-Angiotensin System Genes and Salt Sensitivity Genes on Blood Pressure and Atherosclerosis in the Total Population and Patients With Type 2 Diabetes

Diabetes ◽  
2007 ◽  
Vol 56 (7) ◽  
pp. 1905-1912 ◽  
Author(s):  
M. Yazdanpanah ◽  
Y. S. Aulchenko ◽  
A. Hofman ◽  
J. A.M.J.L. Janssen ◽  
F. A. Sayed-Tabatabaei ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Total Population ◽  
Renin Angiotensin System ◽  
Salt Sensitivity ◽  
Angiotensin System ◽  
Renin Angiotensin

scholarly journals Effects of blood pressure and the renin-angiotensin system on platelet activation in type 2 diabetes

2010 ◽  
Vol 1 (5) ◽  
pp. 196-201 ◽  
Author(s):  
Takashi Uzu ◽  
Masayoshi Sakaguchi ◽  
Atsuko Tsuda ◽  
Aya Kadota ◽  
Yukiyo Yokomaku ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Platelet Activation ◽  
Renin Angiotensin System ◽  
Angiotensin System ◽  
Renin Angiotensin

1071-P: Long-Term Renin-Angiotensin System Inhibitor Use and Risk of Pneumonia and Pneumonia-Related Death in Type 2 Diabetes

Diabetes ◽  
2021 ◽  
Vol 70 (Supplement 1) ◽  
pp. 1071-P
Author(s):  
MAI SHI ◽  
AIMIN YANG ◽  
ERIC S.H. LAU ◽  
HONGJIANG WU ◽  
BAOQI FAN ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Renin Angiotensin System ◽  
Angiotensin System ◽  
Renin Angiotensin
Sign in / Sign up

Export Citation Format

Share Document